Aeglea BioTherapeutics Inc (NASDAQ: AGLE) has acquired Spyre Therapeutics, a privately-held biotechnology firm targeted on creating antibody therapeutics for inflammatory bowel illness.
As a part of the acquisition, Aeglea entered right into a definitive settlement for a non-public placement of Sequence A non-voting convertible most popular inventory, leading to roughly $210 million in gross proceeds.
The funds can be used to advance Spyre’s portfolio of IBD merchandise and assist operations till 2026.
Spyre’s lead applications, concentrating on a4b7 and TL1A, are projected to enter medical research in 2024.
The acquisition and financing transactions present Aeglea with rapid entry to public capital markets and intention to speed up analysis and growth efforts for his or her biologics pipeline.
IBD, which causes continual digestive tract irritation, impacts roughly 1.7 million sufferers within the U.S. The worldwide IBD market, together with Crohn’s illness and ulcerative colitis, is estimated to exceed $29 billion by 2028.
In April, Aeglea BioTherapeutics engaged Wedbush Securities to help in exploring strategic options after the corporate reported disappointing interim outcomes from the Section 1/2 trial of pegtarviliase for Classical Homocystinuria.
Outcomes from the third cohort (1.35 mg/kg) didn’t present a constant discount in homocysteine ranges.
Additional evaluation indicated that contributors within the third cohort developed anti-drug antibodies.
Worth Motion: AGLE shares are up 482.70% at $0.62 in the course of the premarket session on the final examine Thursday.
Do not miss real-time alerts in your shares – be a part of Benzinga Professional at no cost! Attempt the software that may aid you make investments smarter, quicker, and higher.
This text Aeglea BioTherapeutics Inventory Surges Over 400% At the moment – What’s Going On initially appeared on Benzinga.com
.
© 2023 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.